body { -webkit-animation: none; -moz-animation: none; -ms-animation: none; animation: none }

EXPLORE!

FDA Grants Accelerated Approval to Vanrafia for Proteinuria Reduction

428 Views

Emedinexus 07 April 2025

Vanrafia received accelerated FDA approval based on a pre-specified interim analysis from the Phase III ALIGN study, demonstrating a reduction in proteinuria at 36 weeks compared to placebo.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.